Insulet Corp (PODD): Bradley A Thomas , EVP Human Resources of Insulet Corp purchased 1,656 shares on May 5, 2016. The Insider buying transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were purchased at $30.13 per share for a total value of $49,890.14 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 11, 2016, Daniel J Levangie (President, Drug Delivery) sold 12,299 shares at $30.84 per share price.On Mar 3, 2016, Jessica Hopfield (director) purchased 3,230 shares at $30.91 per share price.Also, On Aug 24, 2015, Bradley A Thomas (EVP Human Resources) purchased 845 shares at $29.41 per share price.On Jun 8, 2015, Patrick J Sullivan (CEO) purchased 10,000 shares at $29.39 per share price.
Insulet Corporation: On Wednesday, May 4, 2016 heightened volatility was witnessed in Insulet Corporation which led to swings in the share price. The shares opened for trading at $29.23 and hit $31.58 on the upside , eventually ending the session at $30.25, with a gain of 2.54% or 0.75 points. The heightened volatility saw the trading volume jump to 16,86,440 shares. The 52-week high of the share price is $40.21 and the company has a market cap of $1,729 M . The 52-week low of the share price is at $23.94.
Company has been under the radar of several Street Analysts.Insulet Corporation is Upgraded by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 40 from a previous price target of $30 .Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Feb 26, 2016.
Insulet Corporation is a medical device company engaged in the development manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System) an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica Massachusetts. Features of the OmniPod System include two-part design no tubing and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod a small lightweight disposable insulin infusion device worn beneath clothing; and the PDM a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated hands-free cannula insertion system.